Evaluation of the clinical relevance of anti-annexin-A5 antibodies in Chinese patients with antiphospholipid syndrome
- 21 December 2016
- journal article
- research article
- Published by Springer Nature in Clinical Rheumatology
- Vol. 36 (2) , 407-412
Abstract
A hallmark feature of antiphospholipid syndrome (APS) is the presence of antiphospholipid antibodies (aPLs). Few studies have addressed the clinical relevance of anti-annexin A5 antibodies (aANXA5) in Chinese patients with APS. In this study, we evaluated the clinical performance of aANXA5 in the diagnosis of APS. Sera from 313 subjects were tested, including 170 samples from patients with APS, 104 samples from patients with non-APS diseases as disease controls (DC), and 39 healthy controls (HC). Serum IgG and IgM aANXA5 were determined by ELISA. Overall, the levels of both IgG and IgM aANXA5 were significantly increased in patients with primary APS (PAPS) and APS associated to other diseases (APSAOD) compared with DC and HC. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for IgG and IgM aANXA5 in the diagnosis of APS were 33.5 and 15.3, 99.0 and 99.0, 98.3 and 96.3, and 47.7 and 41.7%, respectively. Significant associations between IgG aANXA5 and arterial thrombotic events (OR, 2.60; 95% CI, 1.44–4.71) and between IgG aANXA5 and venous thrombotic events (OR, 2.80; 95% CI, 1.55–5.06) were identified. No correlations were identified between IgG or IgM aANXA5 and obstetric complications. Our data suggest that aANXA5 could serve as a diagnosis biomarker for patients with APS. More importantly, our data highlighted a potential role of IgG aANXA5 in identifying APS patients with high risk of thrombosis.Keywords
Funding Information
- National Natural Science Foundation of China (81373188)
This publication has 24 references indexed in Scilit:
- Role of anti‐annexin A5 in pathogenesis of hypercoagulable state in patients with antiphospholipid syndromeInternational Journal of Rheumatic Diseases, 2013
- Anti-annexins autoantibodies: Their role as biomarkers of autoimmune diseasesAutoimmunity Reviews, 2011
- The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosisLupus, 2010
- Clinical course of high‐risk patients diagnosed with antiphospholipid syndromeJournal of Thrombosis and Haemostasis, 2010
- Annexin A5 polymorphism (−1C→T) and the presence of anti-annexin A5 antibodies in the antiphospholipid syndromeAnnals of the Rheumatic Diseases, 2006
- International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)Journal of Thrombosis and Haemostasis, 2006
- A Prospective Study of 1038 Pregnancies on the Predictive Value of Anti‐Annexin V Antibodies for Fetal LossAnnals of the New York Academy of Sciences, 2005
- Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndromeBlood, 2004
- Elevated Anti–Annexin V Antibody Levels in Antiphospholipid Syndrome and Their Involvement in Antiphospholipid Antibody SpecificitiesAmerican Journal of Clinical Pathology, 2000
- Anti‐annexin V antibody in systemic lupus erythematosus patients with lupus anticoagulant and/or anticardiolipin antibodyAmerican Journal of Hematology, 1994